Trial Profile
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma; CNS cancer; Intraocular lymphoma; Lymphomatous meningitis; Non-Hodgkin's lymphoma
- Focus Proof of concept; Therapeutic Use
- Acronyms iLOC
- 06 Apr 2022 Status changed from active, no longer recruiting to completed.
- 30 Mar 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 03 Jul 2019 Results published in the European Journal of Cancer